News|Articles|December 8, 2025
Low-pg/mL quantification of TL 13-112, a proteolysistargeting chimera (PROTAC) in rat plasma
Author(s)SCIEX
This technical note demonstrates a highly sensitive, robust and rapid workflow to quantify TL 13-112, a selective ALK degrader, and its inactive control, TL 13-110, in rat plasma using a high-end triple quadrupole mass spectrometer.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Novartis Calls for Global Governments to Address Global Trade Policy
3
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
4
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
5